Jonathan Wong, Emily Gruber, Belinda Maher, Mark Waltham, Zahra Sabouri-Thompson, Ian Jong, Quinton Luong, Sidney Levy, Beena Kumar, Daniella Brasacchio, Wendy Jia, Joan So, Hugh Skinner, Alexander Lewis, Simon J Hogg, Stephin Vervoort, Carmen DiCorleto, Micheleine Uhe, Jeanette Gamgee, Stephen Opat, Gareth P Gregory, Galina Polekhina, John Reynolds, Eliza A Hawkes, Gajan Kailainathan, Robin Gasiorowski, Lev M Kats, Jake Shortt
Peripheral T-cell lymphoma (PTCL) is a rare, heterogenous malignancy with dismal outcomes at relapse. Hypomethylating agents (HMA) have an emerging role in PTCL, supported by shared mutations with myelodysplasia (MDS). Response rates to azacitidine in PTCL of follicular helper cell origin are promising. Guadecitabine is a decitabine analogue with efficacy in MDS. In this phase II, single-arm trial, PTCL patients received guadecitabine on days 1-5 of 28-day cycles. Primary end points were overall response rate (ORR) and safety...
June 2022: Leukemia